Innovative drugs and CRO concepts fluctuated and declined, with PharmaBlock Sciences falling more than 10%.

Innovative drugs and CRO concepts fluctuated and declined. Hongbo Pharmaceutical and ACROBiosystems fell more than 10%, Apeloa Pharmaceutical hit the limit down, and Lummy Pharmaceutical, Novoprotein, JENKEM Technology, and GemPharmatech were among the biggest decliners.